<DOC>
	<DOCNO>NCT00575796</DOCNO>
	<brief_summary>The overall objective study determine efficacy weekly Vinblastine chemotherapy na√Øve patient progressive incompletely resect paediatric low grade glioma , generate estimate response rate , progression-free survival , toxicity quality daily living among population treat determine biologic factor enable u predict tumour behaviour .</brief_summary>
	<brief_title>Weekly Vinblastine Chemotherapy Naive Children With Progressive Low Grade Glioma ( PLGGs )</brief_title>
	<detailed_description>Unresectable low grade glioma ( LGG ) childhood increasingly appear chronic condition multiple treatment may require . While several study show evidence short term tumour control chemotherapy , progression-free survival 5 year unsatisfactory . In addition , several regimen currently use condition associate significant risk side effect long term toxicity . We pilot single arm study feasibility efficacy Vinblastine child recurrent refractory low grade glioma , fail least one line treatment ( chemotherapy and/or irradiation ) . Preliminary result show promising activity minimal toxicity .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Patients must &lt; 18 year age originally diagnose . 2 . Histologic Diagnosis : Patients must histologic verification LGG original diagnosis . Exceptions optic pathway gliomas child neurofibromatosis child large hypothalamic tumour diagnostic biopsy seem necessary . Patients disseminate low grade glioma eligible . 1 . Astrocytoma Variants : fibrillary , protoplasmic , gemistocytic , mixed 2 . Pilocytic Astrocytoma 3 . Pleomorphic Xanthoastrocytoma 4 . Infantile desmoplastic astrocytoma 5 . Ganglioglioma 6 . Oligodendroglioma 7 . Mixed glioma ( include oligoastrocytoma ) 8 . Pilomyxoid astrocytoma 3 . Performance Level : Patients must ECOG performance status 0 , 1 2 Lansky/Karnofsky score &gt; 50 4 . Life expectancy : Patients must life expectancy * 2 month . 5 . Prior Therapy : Patients eligible time diagnosis first progression follow treatment surgery . 6 . Measurable Disease : Patients must measurable disease , document radiographic criterion . 7 . Concomitant Medications 1 . Steroids : Steroids may use time inclusion control progressive symptom . 2 . Antiepileptic medication permit levetiracetam ( Keppra ) clobazam ( Frisium ) prefer antiepileptic medication chronic use reserve phenytoin lorazepam acute seizure control . 8 . Organ Function Requirements : All patient must adequate organ bone marrow function within 7 day start chemotherapy ( ANC * 1.0 x 109/L / , platelet count * 100 x 109/L ( transfusion independent ) . 9 . Regulatory : All patient and/or parent legal guardian must sign write informed consent institutional requirement human study must meet . This study open participant regardless gender ethnicity . Inclusion criterion restrictive . Patient must meet inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>pediatrics</keyword>
	<keyword>Low Grade Glioma</keyword>
	<keyword>Vinblastine</keyword>
</DOC>